| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1015893542 |
| P356 | DOI | 10.1080/13550280590922748 |
| P698 | PubMed publication ID | 16036796 |
| P5875 | ResearchGate publication ID | 7708327 |
| P2093 | author name string | Ming Li | |
| Janice E Clements | |||
| M Christine Zink | |||
| Joseph L Mankowski | |||
| Lucio Gama | |||
| Brandon Bullock | |||
| Lucy M Carruth | |||
| P2860 | cites work | Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy | Q28253761 |
| Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy | Q29615992 | ||
| Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy | Q29615993 | ||
| Recovery of replication-competent HIV despite prolonged suppression of plasma viremia | Q29615995 | ||
| Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection | Q29619738 | ||
| The changing pattern of HIV neuropathology in the HAART era. | Q30797688 | ||
| Pharmacokinetics and metabolism of racemic 2',3'-dideoxy-5-fluoro-3'-thiacytidine in rhesus monkeys | Q33745246 | ||
| High viral load in the cerebrospinal fluid and brain correlates with severity of simian immunodeficiency virus encephalitis. | Q33825647 | ||
| HIV-1 can be recovered from a variety of cells including peripheral blood monocytes of patients receiving highly active antiretroviral therapy: a further obstacle to eradication | Q33917711 | ||
| Molecular analysis of cerebrospinal fluid: potential for the study of HIV-1 infection of the central nervous system | Q33953033 | ||
| The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors | Q34065800 | ||
| Basic principles of immunological surveillance of the normal central nervous system | Q34398602 | ||
| Reservoirs for HIV infection and their persistence in the face of undetectable viral load | Q34426036 | ||
| Resting CD4+ T lymphocytes but not thymocytes provide a latent viral reservoir in a simian immunodeficiency virus-Macaca nemestrina model of human immunodeficiency virus type 1-infected patients on highly active antiretroviral therapy | Q34857454 | ||
| Searching for clues: tracking the pathogenesis of human immunodeficiency virus central nervous system disease by use of an accelerated, consistent simian immunodeficiency virus macaque model | Q34993089 | ||
| A novel simian immunodeficiency virus model that provides insight into mechanisms of human immunodeficiency virus central nervous system disease | Q35030075 | ||
| Changing patterns in the neuropathogenesis of HIV during the HAART era. | Q35126422 | ||
| Antiviral treatment normalizes neurophysiological but not movement abnormalities in simian immunodeficiency virus-infected monkeys | Q35128071 | ||
| Patterns of viral replication correlate with outcome in simian immunodeficiency virus (SIV)-infected macaques: effect of prior immunization with a trivalent SIV vaccine in modified vaccinia virus Ankara. | Q35861490 | ||
| Molecular and biological characterization of a neurovirulent molecular clone of simian immunodeficiency virus | Q35889564 | ||
| Pathogenesis of simian immunodeficiency virus encephalitis: viral determinants of neurovirulence | Q35890115 | ||
| Evidence for human immunodeficiency virus type 1 replication in vivo in CD14(+) monocytes and its potential role as a source of virus in patients on highly active antiretroviral therapy | Q39685944 | ||
| Relative potency of protease inhibitors in monocytes/macrophages acutely and chronically infected with human immunodeficiency virus. | Q41018028 | ||
| Expression kinetics and subcellular localization of HIV-1 regulatory proteins Nef, Tat and Rev in acutely and chronically infected lymphoid cell lines | Q41504229 | ||
| Time course of cerebrospinal fluid responses to antiretroviral therapy: evidence for variable compartmentalization of infection. | Q41677720 | ||
| Cerebrospinal fluid HIV RNA originates from both local CNS and systemic sources | Q41721709 | ||
| Changes in pathological findings at autopsy in AIDS cases for the last 15 years | Q41724548 | ||
| Anti-retrovirus activity of 9-(2-phosphonylmethoxyethyl)adenine (PMEA) in vivo increases when it is less frequently administered | Q42831609 | ||
| Plasma SIV RNA viral load determination by real-time quantification of product generation in reverse transcriptase-polymerase chain reaction | Q44244285 | ||
| Beta-chemokines MCP-1 and RANTES are selectively increased in cerebrospinal fluid of patients with human immunodeficiency virus-associated dementia | Q44253971 | ||
| Cerebrospinal fluid HIV-1 RNA during treatment with ritonavir/saquinavir or ritonavir/saquinavir/stavudine | Q44527304 | ||
| The central nervous system as a reservoir for simian immunodeficiency virus (SIV): steady-state levels of SIV DNA in brain from acute through asymptomatic infection | Q45730919 | ||
| Increased macrophage chemoattractant protein-1 in cerebrospinal fluid precedes and predicts simian immunodeficiency virus encephalitis | Q45735521 | ||
| Comparative assessment of antiretrovirals in human monocyte-macrophages and lymphoid cell lines acutely and chronically infected with the human immunodeficiency virus | Q45846545 | ||
| HIV-related neuropathology, 1985 to 1999: rising prevalence of HIV encephalopathy in the era of highly active antiretroviral therapy | Q46103833 | ||
| Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy | Q47960975 | ||
| HIV-1 infection of subcortical astrocytes in the pediatric central nervous system | Q48162348 | ||
| Overexpression of nef as a marker for restricted HIV-1 infection of astrocytes in postmortem pediatric central nervous tissues | Q48162358 | ||
| Astrocytes: HIV cellular reservoirs and important participants in neuropathogenesis | Q48235017 | ||
| Effect of genotypic resistance on the virological response to highly active antiretroviral therapy in cerebrospinal fluid | Q48372719 | ||
| Cervical lymphatics, the blood-brain barrier and the immunoreactivity of the brain: a new view | Q48400195 | ||
| In vitro blood-brain barrier permeability of nevirapine compared to other HIV antiretroviral agents | Q48497171 | ||
| Monocytes harbour replication-competent, non-latent HIV-1 in patients on highly active antiretroviral therapy. | Q52021616 | ||
| Detection of infectious HIV in circulating monocytes from patients on prolonged highly active antiretroviral therapy. | Q54057499 | ||
| Persistence of HIV-1 Transcription in Peripheral-Blood Mononuclear Cells in Patients Receiving Potent Antiretroviral Therapy | Q57075703 | ||
| In vitro activity of inhibitors of late stages of the replication of HIV in chronically infected macrophages | Q72182519 | ||
| Investigation of distribution, transport and uptake of anti-HIV drugs to the central nervous system | Q73850558 | ||
| Neuropathology and general autopsy findings in AIDS during the last 15 years | Q74237358 | ||
| Changes to AIDS dementia complex in the era of highly active antiretroviral therapy | Q78029535 | ||
| P433 | issue | 2 | |
| P921 | main subject | patient | Q181600 |
| Simian immunodeficiency virus | Q1890246 | ||
| anti-retroviral agent | Q50430310 | ||
| P304 | page(s) | 180-189 | |
| P577 | publication date | 2005-04-01 | |
| P1433 | published in | Journal of NeuroVirology | Q6295640 |
| P1476 | title | The central nervous system is a viral reservoir in simian immunodeficiency virus--infected macaques on combined antiretroviral therapy: a model for human immunodeficiency virus patients on highly active antiretroviral therapy | |
| P478 | volume | 11 |
| Q92709577 | A Tat/Rev Induced Limiting Dilution Assay to Measure Viral Reservoirs in Non-Human Primate Models of HIV Infection |
| Q37617639 | A coat of many colors: neuroimmune crosstalk in human immunodeficiency virus infection |
| Q48088860 | A mouse model of HIV-associated neurocognitive disorders: a brain-behavior approach to discover disease mechanisms and novel treatments. |
| Q37177226 | A single amino acid change and truncated TM are sufficient for simian immunodeficiency virus to enter cells using CCR5 in a CD4-independent pathway |
| Q26767476 | Animal Models for HIV Cure Research |
| Q37041160 | Animal models to achieve an HIV cure |
| Q37333388 | Assessing HIV and AIDS treatment safety and health-related quality of life among cohort of Malaysian patients: a discussion on methodological approach |
| Q90442994 | Brain is a potential sanctuary for subtype C HIV-1 irrespective of ART treatment outcome |
| Q35023230 | CB2 receptor agonists protect human dopaminergic neurons against damage from HIV-1 gp120. |
| Q35195923 | Cerebrospinal fluid is an efficient route for establishing brain infection with feline immunodeficiency virus and transfering infectious virus to the periphery |
| Q48080546 | Comparative study of the perceived quality of life of patients in treatment for cocaine and heroin dependence in Spain: differences by gender and time in treatment. |
| Q37354047 | Compartmentalized HIV rebound in the central nervous system after interruption of antiretroviral therapy |
| Q26825814 | Considerations in the development of nonhuman primate models of combination antiretroviral therapy for studies of AIDS virus suppression, residual virus, and curative strategies |
| Q36802400 | Contributors to neuropsychological impairment in HIV-infected and HIV-uninfected opiate-dependent patients |
| Q33519523 | Coordinated regulation of SIV replication and immune responses in the CNS. |
| Q41926815 | Defining total-body AIDS-virus burden with implications for curative strategies |
| Q45208463 | Depressive symptoms and neurocognitive performance among HIV-infected women |
| Q37352656 | Different levels of HIV DNA copy numbers in cerebrospinal fluid cellular subsets |
| Q36629330 | Differing HIV risks and prevention needs among men and women injection drug users (IDU) in the District of Columbia. |
| Q37094265 | Early detection of simian immunodeficiency virus in the central nervous system following oral administration to rhesus macaques |
| Q35965672 | Early minocycline treatment prevents a decrease in striatal dopamine in an SIV model of HIV-associated neurological disease |
| Q34596417 | Effect of suberoylanilide hydroxamic acid (SAHA) administration on the residual virus pool in a model of combination antiretroviral therapy-mediated suppression in SIVmac239-infected indian rhesus macaques |
| Q34057907 | Emergence of CD4 independence envelopes and astrocyte infection in R5 simian-human immunodeficiency virus model of encephalitis |
| Q42588135 | Endothelial cell suppression of peripheral blood mononuclear cell trafficking in vitro during acute exposure to feline immunodeficiency virus |
| Q35252186 | Eradicating HIV-1 infection: seeking to clear a persistent pathogen |
| Q33813281 | Factors associated with depressive symptoms in African American crack cocaine smokers |
| Q38790617 | Fate of microglia during HIV-1 infection: From activation to senescence? |
| Q34646361 | Gender Roles and Mental Health in Women With and at Risk for HIV. |
| Q51808008 | Gender and age differences in quality of life and the impact of psychopathological symptoms among HIV-infected patients. |
| Q43168966 | Gender differences in social support and depression among injection drug users in Houston, Texas |
| Q37015469 | HIV Preclinical-Clinical Therapeutics Research: central nervous system approaches |
| Q36090743 | HIV status and gender: a brief report from heterosexual couples in Thailand |
| Q36034222 | HIV-1 Tat and cocaine mediated synaptopathy in cortical and midbrain neurons is prevented by the isoflavone Equol. |
| Q45358191 | Identification of psychiatric disorders among human immunodeficiency virus-infected individuals in Taiwan, a nine-year nationwide population-based study |
| Q37919370 | Immunomodulatory properties of kappa opioids and synthetic cannabinoids in HIV-1 neuropathogenesis |
| Q52607097 | Impact of Antiretroviral Regimens on CSF Viral Escape in a Prospective Multicohort Study of ART-Experienced HIV-1 Infected Adults in the United States. |
| Q34033558 | Impact of short-term combined antiretroviral therapy on brain virus burden in simian immunodeficiency virus-infected and CD8+ lymphocyte-depleted rhesus macaques |
| Q93186350 | Impacts of HIV Cure Interventions on Viral Reservoirs in Tissues |
| Q39315707 | In Vivo Models of Human Immunodeficiency Virus Persistence and Cure Strategies |
| Q34691336 | Inhibition of highly productive HIV-1 infection in T cells, primary human macrophages, microglia, and astrocytes by Sargassum fusiforme |
| Q35787684 | Monocyte maturation, HIV susceptibility, and transmigration across the blood brain barrier are critical in HIV neuropathogenesis |
| Q37968178 | Monocyte mobilization, activation markers, and unique macrophage populations in the brain: observations from SIV infected monkeys are informative with regard to pathogenic mechanisms of HIV infection in humans |
| Q28751900 | Monocyte/macrophage trafficking in acquired immunodeficiency syndrome encephalitis: lessons from human and nonhuman primate studies |
| Q37089861 | NeuroAIDS: characteristics and diagnosis of the neurological complications of AIDS. |
| Q35177355 | Neuroimmunity and the blood-brain barrier: molecular regulation of leukocyte transmigration and viral entry into the nervous system with a focus on neuroAIDS. |
| Q33590337 | Neurologic presentations of AIDS. |
| Q42200917 | Novel pathway for induction of latent virus from resting CD4(+) T cells in the simian immunodeficiency virus/macaque model of human immunodeficiency virus type 1 latency. |
| Q37169285 | Robust suppression of env-SHIV viremia in Macaca nemestrina by 3-drug ART is independent of timing of initiation during chronic infection |
| Q37155048 | SIV replication is directly downregulated by four antiviral miRNAs. |
| Q34320963 | Screening for neurocognitive impairment, depression, and anxiety in HIV-infected patients in Western Europe and Canada. |
| Q37371300 | Second assessment of NeuroAIDS in Africa |
| Q48204292 | Self-esteem and quality of life of people living with HIV/AIDS. |
| Q41886197 | Sex differences in HIV effects on visual memory among substance-dependent individuals |
| Q33962223 | Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy |
| Q48644297 | Social context of rural Women with HIV/AIDS. |
| Q44407171 | Subcortical profile of memory compromise among HIV-1-infected individuals |
| Q30411844 | The role of host genetics in the susceptibility for HIV-associated neurocognitive disorders |
| Q37781306 | Thinking about HIV: the intersection of virus, neuroinflammation and cognitive dysfunction |
| Q37200979 | Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy |
| Q26825231 | Unraveling the pathogenesis of HIV peripheral neuropathy: insights from a simian immunodeficiency virus macaque model |
| Q28077662 | Using animal models to overcome temporal, spatial and combinatorial challenges in HIV persistence research |
| Q37390163 | Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system |
Search more.